Cargando…

Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review

BACKGROUND: Ovarian cancer (OC) is a common malignancy in the gynecological tumor. Standard treatment for ovarian cancer is surgery and chemotherapy based on paclitaxel and platinum. However, traditional chemotherapy for ovarian cancer is limited by drug resistance and systemic side effects. It is i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Chunmei, Xu, Fangye, Wang, Rong, Liang, Qi, Shen, Kai, Xu, Jiali, Liu, Lianke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646866/ https://www.ncbi.nlm.nih.gov/pubmed/34880628 http://dx.doi.org/10.2147/OTT.S335139

Ejemplares similares

A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
por: Xu, Fangye, et al.
Publicado: (2022)

Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model
por: Jin, Yinghua, et al.
Publicado: (2018)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers
por: Chen, Weijie, et al.
Publicado: (2011)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report
por: Zhang, Mingzi, et al.
Publicado: (2017)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019)

Primary pulmonary arterial sarcoma treated with endostar injection and radiotherapy
por: Xu, Hui, et al.
Publicado: (2020)

Primary pulmonary arterial sarcoma treated with Endostar injection and radiotherapy
por: Xu, Hui, et al.
Publicado: (2020)

Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin
por: Yang, Lingge, et al.
Publicado: (2019)

Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
por: Zhang, Di, et al.
Publicado: (2019)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report
por: Han, Tao, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma
por: Han, Xinghua, et al.
Publicado: (2017)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
por: Hou, Zhiguo, et al.
Publicado: (2023)

Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer
por: Lu, Heming, et al.
Publicado: (2022)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature
por: XU, MINGFANG, et al.
Publicado: (2014)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yin, Yuanxiu, et al.
Publicado: (2022)

Papillary squamous cell carcinoma successfully treated with bronchoscopic intratumoral injections of cisplatin and Endostar: a case report
por: Wang, Yong, et al.
Publicado: (2021)

The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer
por: Pu, Zhaoxia, et al.
Publicado: (2015)

Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment
por: Chen, Siying, et al.
Publicado: (2021)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Apatinib in refractory radiation-induced brain edema: A case report
por: Hu, Wei Guo, et al.
Publicado: (2017)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation
por: Hu, Sanyuan, et al.
Publicado: (2010)

αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
por: Fang, Juemin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cm4hm4ib3vbsvf4d8o4aqaaeo9